- Home
- NIE vs RGNX Comparison
NIE vs RGNX Comparison
Compare NIE & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- RGNX
- Stock Information
- Founded
- NIE 2007
- RGNX 2008
- Country
- NIE United States
- RGNX United States
- Employees
- NIE N/A
- RGNX N/A
- Industry
- NIE Investment Managers
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NIE Finance
- RGNX Health Care
- Exchange
- NIE Nasdaq
- RGNX Nasdaq
- Market Cap
- NIE 700.2M
- RGNX 661.2M
- IPO Year
- NIE N/A
- RGNX 2015
- Fundamental
- Price
- NIE $25.23
- RGNX $12.59
- Analyst Decision
- NIE
- RGNX Strong Buy
- Analyst Count
- NIE 0
- RGNX 7
- Target Price
- NIE N/A
- RGNX $30.00
- AVG Volume (30 Days)
- NIE 70.5K
- RGNX 653.4K
- Earning Date
- NIE 01-01-0001
- RGNX 11-04-2025
- Dividend Yield
- NIE 9.04%
- RGNX N/A
- EPS Growth
- NIE N/A
- RGNX N/A
- EPS
- NIE N/A
- RGNX N/A
- Revenue
- NIE N/A
- RGNX $155,782,000.00
- Revenue This Year
- NIE N/A
- RGNX $203.79
- Revenue Next Year
- NIE N/A
- RGNX $0.72
- P/E Ratio
- NIE N/A
- RGNX N/A
- Revenue Growth
- NIE N/A
- RGNX 74.95
- 52 Week Low
- NIE $18.61
- RGNX $5.04
- 52 Week High
- NIE $22.47
- RGNX $13.39
- Technical
- Relative Strength Index (RSI)
- NIE 50.70
- RGNX 61.27
- Support Level
- NIE $24.91
- RGNX $11.50
- Resistance Level
- NIE $25.57
- RGNX $13.39
- Average True Range (ATR)
- NIE 0.36
- RGNX 0.83
- MACD
- NIE -0.05
- RGNX 0.08
- Stochastic Oscillator
- NIE 33.33
- RGNX 74.29
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.